50 results
6-K
EX-99.3
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
MC Services AG
Email: IR@inflarx.de
Katja Arnold, Laurie Doyle
6-K
EX-99.1
IFRX
InflaRx N.V.
30 Aug 23
Current report (foreign)
8:00am
work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
responsibility for medical affairs. In addition, we are building the necessary infrastructure, including IT systems, supply chain, financial reporting systems
6-K
EX-99.3
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
MC Services AG
424B5
a5ntj6mp38fqts65ws
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.2
cczzhy
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
deix1c3yajm
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
ngozmgwq4bxdbjw
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.3
vzhyvo2oej 2yp
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
yx31g
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.3
4vuk 07p9p1k
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
8vlota3ggevc9d23b
13 Apr 23
Current report (foreign)
4:01pm
424B5
ky2vdzv0rw660h 1unmt
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
sig8n9u60xz
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
fxpg 0arfk7i
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
ndd6648ubyfn8nbk6p2
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.4
ba74t8aw9ffdm7cf43l
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
c3ny 4wz5
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
EX-99.1
0an 3ezkg9
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am